Immunological insights into COVID-19 in Southern Nigeria

Author:

Ugwu Chinedu A.,Alao Oluwasina,John Oluwagboadurami G.,Akinnawo Blossom,Ajayi Israel,Odebode Ooreofe,Bejide Ifeoluwa,Campbell Allan,Campbell Julian,Adole Jolly A.,B. Olawoye Idowu,Akano Kazeem,Okolie Johnson,Eromon Philomena,Olaitan Peter,Olagunoye Ajibola,Adebayo Ibukun,Adebayo Victor,Babalola Elizabeth,Abioye Omowumi,Ajayi Nnennaya,Ogah Emeka,Ukwaja Kingsley,Okoro Sylvanus,Oje Ogbonnaya,Kingsley Ojide Chiedozie,Eke Matthew,Onyia Venatius,Achonduh-Atijegbe Olivia,Ewah Friday Elechi,Obasi Mary,Igwe Violet,Ayodeji Olufemi,Chukwuyem Abejegah,Owhin Sampson,Oyejide Nicholas,Abah Sylvester,Ingbian Winifred,Osoba Moyosoore,Alebiosu Ahmed,Nadesalingam Angalee,Aguinam Ernest T.,Carnell George,Krause Nina,Chan Andrew,George Charlotte,Kinsley Rebecca,Tonks Paul,Temperton Nigel,Heeney Jonathan,Happi Christian

Abstract

IntroductionOne of the unexpected outcomes of the COVID-19 pandemic was the relatively low levels of morbidity and mortality in Africa compared to the rest of the world. Nigeria, Africa's most populous nation, accounted for less than 0.01% of the global COVID-19 fatalities. The factors responsible for Nigeria's relatively low loss of life due to COVID-19 are unknown. Also, the correlates of protective immunity to SARS-CoV-2 and the impact of pre-existing immunity on the outcome of the COVID-19 pandemic in Africa are yet to be elucidated. Here, we evaluated the natural and vaccine-induced immune responses from vaccinated, non-vaccinated and convalescent individuals in Southern Nigeria throughout the three waves of the COVID-19 pandemic in Nigeria. We also examined the pre-existing immune responses to SARS-CoV-2 from samples collected prior to the COVID-19 pandemic.MethodsWe used spike RBD and N- IgG antibody ELISA to measure binding antibody responses, SARS-CoV-2 pseudotype assay protocol expressing the spike protein of different variants (D614G, Delta, Beta, Omicron BA1) to measure neutralizing antibody responses and nucleoprotein (N) and spike (S1, S2) direct ex vivo interferon gamma (IFNγ) T cell ELISpot to measure T cell responses. ResultOur study demonstrated a similar magnitude of both binding (N-IgG (74% and 62%), S-RBD IgG (70% and 53%) and neutralizing (D614G (49% and 29%), Delta (56% and 47%), Beta (48% and 24%), Omicron BA1 (41% and 21%)) antibody responses from symptomatic and asymptomatic survivors in Nigeria. A similar magnitude was also seen among vaccinated participants. Interestingly, we revealed the presence of preexisting binding antibodies (N-IgG (60%) and S-RBD IgG (44%)) but no neutralizing antibodies from samples collected prior to the pandemic. DiscussionThese findings revealed that both vaccinated, non-vaccinated and convalescent individuals in Southern Nigeria make similar magnitude of both binding and cross-reactive neutralizing antibody responses. It supported the presence of preexisting binding antibody responses among some Nigerians prior to the COVID-19 pandemic. Lastly, hybrid immunity and heterologous vaccine boosting induced the strongest binding and broadly neutralizing antibody responses compared to vaccine or infection-acquired immunity alone.

Funder

Bill and Melinda Gates Foundation

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference26 articles.

1. Coronavirus Cases: Deaths: Recovered: Nigeria COVID - Coronavirus Statistics - Worldometer2023

2. Why is there low morbidity and mortality of COVID-19 in africa;Njenga;Am J Trop Med Hyg,2020

3. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study;Watson;Lancet Infect Dis,2021

4. The impact of COVID-19 vaccines on the Case Fatality Rate: The importance of monitoring breakthrough infections;Sánchez-romero;Int J Infect Dis,2022

5. The T cell immune response against SARS-CoV-2;Moss;Nat Immunol,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3